Mohammad Y Zaidi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4428874/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surgery, 2019, 154, 134.	2.2	54
2	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, 270, 422-433.	2.1	53
3	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. Annals of Surgical Oncology, 2019, 26, 2517-2524.	0.7	38
4	The conundrum of < 2-cm pancreatic neuroendocrine tumors: AÂpreoperative risk score to predict lymph node metastases and guide surgical management. Surgery, 2019, 166, 15-21.	1.0	34
5	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 150-160.	1.9	30
6	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2020, 24, 155-164.	0.9	27
7	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. Journal of Gastrointestinal Surgery, 2020, 24, 165-176.	0.9	26
8	The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multiâ€institutional propensity score analysis from the US Sarcoma Collaborative. Journal of Surgical Oncology, 2019, 120, 332-339.	0.8	25
9	Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?. Journal of Surgical Oncology, 2019, 120, 611-623.	0.8	21
10	Caution: Increased Acute Kidney Injury in Enhanced Recovery after Surgery (ERAS) Protocols. American Surgeon, 2019, 85, 156-161.	0.4	21
11	Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative. World Journal of Gastrointestinal Oncology, 2020, 12, 756-767.	0.8	21
12	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Annals of Surgical Oncology, 2020, 27, 783-792.	0.7	20
13	Postâ€operative surveillance in retroperitoneal soft tissue sarcoma: The importance of tumor histology in guiding strategy. Journal of Surgical Oncology, 2018, 117, 99-104.	0.8	19
14	Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. Annals of Surgical Oncology, 2019, 26, 3542-3549.	0.7	19
15	Duodenal neuroendocrine tumors: Somewhere between the pancreas and small bowel?. Journal of Surgical Oncology, 2019, 120, 1293-1301.	0.8	19
16	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Annals of Surgical Oncology, 2019, 26, 2234-2240.	0.7	16
17	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4980-4995.	0.7	15
18	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surgical Oncology, 2021, 37, 101492.	0.8	15

#	Article	IF	CITATIONS
19	Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 134-146.	0.7	14
20	What is the Optimal Preoperative Imaging Modality for Assessing Peritoneal Cancer Index? An Analysis From the United States HIPEC Collaborative. Clinical Colorectal Cancer, 2020, 19, e1-e7.	1.0	14
21	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 156-164.	0.7	13
22	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	0.4	13
23	A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique. Journal of Surgical Oncology, 2019, 120, 932-939.	0.8	11
24	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 2020, 27, 4894-4907.	0.7	11
25	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. Journal of Surgical Oncology, 2020, 122, 980-985.	0.8	10
26	Identifying the barriers to gastric cancer care at safetyâ€net hospitals: A novel comparison of a safetyâ€net hospital to a neighboring quaternary referral academic center in the same healthcare system. Journal of Surgical Oncology, 2019, 119, 64-70.	0.8	9
27	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4996-5004.	0.7	8
28	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â€institution study from the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2019, 119, 5-11.	0.8	5
29	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. Journal of Gastrointestinal Surgery, 2020, 24, 1138-1148.	0.9	5
30	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. International Journal of Hyperthermia, 2020, 37, 1182-1188.	1.1	5
31	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. British Journal of Cancer, 2020, 123, 1377-1386.	2.9	4
32	The Utility of Preoperative Tumor Markers in Peritoneal Carcinomatosis from Primary Appendiceal Adenocarcinoma: an Analysis from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2021, 25, 2908-2919.	0.9	4
33	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. Journal of Gastrointestinal Surgery, 2022, 26, 414-424.	0.9	3
34	Lending a hand for laparoscopic distal pancreatectomy: the optimal approach?. Hpb, 2020, 22, 690-701.	0.1	2
35	A closer look at the natural history and recurrence patterns of high-grade truncal/extremity leiomyosarcomas: A multi-institutional analysis from the US Sarcoma Collaborative. Surgical Oncology, 2020, 34, 292-297.	0.8	2
36	The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz?. Journal of Gastrointestinal Surgery, 2020, 24, 2046-2053.	0.9	0